Hot Picks

AI-vetted picks: crashed companies whose fundamentals still hold up.

Earlier picks 3

Everything the screener has flagged before, most recent first.

C

🔥 HOT detected 2026-10-01 Fundamentals67/100

✓Buy: Buy — a real multi-year turnaround (rising profits, shrinking share count via buybacks) is underway, and the recent dip looks like normal noise, not new bad news.

Declined -76.8% from its all-time high of $557.00 — now $129.48

I bought this

Full analysis & scorecard›

What's going on

The stock never recovered from the 2008 financial crisis and years of stagnation, but that's ancient history — recently Citigroup has been executing a genuine turnaround under CEO Jane Fraser (divesting weak international consumer units, cutting costs) and the modest 6.7% dip from its 30-day high appears to be routine pre-earnings jitters, not a specific negative event.

The case for it

Citigroup's profitability is clearly improving: net income was $5.8 billion, up from $4.0 billion a year earlier, with EPS of $3.15 up from $1.96, helped by a shrinking share count from buybacks. Management is returning huge amounts of cash to shareholders — the board authorized a $30-billion buyback commitment in June 2026, with no expiry date — while targeting materially higher returns: Citi raised its near-term return target to 11% to 13% ROTCE for 2027 and 2028, with a medium-term path to 14% to 15%. At a forward P/E around 10 and trading ~20% below the average analyst target, the market hasn't fully priced in this improving earnings trajectory.

What could go wrong

Citigroup's return on equity, while improving, is still structurally weaker than peers like JPMorgan, the balance sheet score in this screen is very low (8/25) reflecting a huge, leverage-heavy bank, and execution risk is real — if the Oct 13 earnings disappoint or regulatory capital requirements tighten, the turnaround narrative could stall as it has multiple times over the past decade.

Fwd P/E 10.0Op margin 36.2%Rev growth 15.5%Debt/equity —Analyst upside 19.6%

How this scored 67/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 21.8%

✅ Generates cash Free cash flow unknown

✅ Not drowning in debt Debt/equity unknown — exempt (banks run on leverage by design)

✅ Can pay its bills Exempt (financials)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 18/25

Operating margin 36.2% 9/9

Net profit margin 21.8% 8/8

Return on equity 8.5% 1/8

Growth Is it getting bigger, or dying? 22/25

Revenue growth 15.5% 6/9

Earnings growth 61.0% 8/8

Expected profit change 39.0% 8/8

Value Is it cheap right now? 19/25

Forward P/E 10.0 9/10

PEG ratio 0.6 8/8

Analyst target upside 19.6% 2/7

Balance sheet Will it survive? 8/25

Debt / equity unknown 3/10

Current ratio unknown 2/8

Free cash flow unknown 2/7

source · source · source · source

GRAB

🔥 HOT detected 2026-09-30 Fundamentals64/100

✓Buy: Buy — Grab just turned solidly profitable and raised guidance, but the stock dropped on regulatory noise, not a business breakdown.

Declined -81.4% from its all-time high of $16.75 — now $3.12

I bought this

Full analysis & scorecard›

What's going on

The stock's massive long-term collapse traces back to its wildly overpriced 2021 SPAC listing at a $40B valuation for a then loss-making company; that overvaluation has been unwinding for years. The recent ~14% pullback from the 30-day high is driven by a mix of macro jitters (rising yields/oil), a Vietnam regulatory probe into driver fares, driver protests, a large $1.49B Atome fintech acquisition spooking investors, and CEO insider selling — not a collapse in the actual business.

The case for it

Grab's most recent quarter showed real operating improvement: revenue up 22%, net income jumping to $252M with a 25% profit margin (versus 4.3% a year earlier), and management raised full-year 2026 revenue guidance. The balance sheet is strong with $6.53B cash against only $2.03B debt, giving plenty of cushion to absorb the Atome acquisition and any regulatory fines. Wall Street analysts overwhelmingly rate it a "Strong Buy" with average price targets around $5.9-$7.4, implying large upside from today's $3.12, because they see the recent dip as noise around a company that is finally scaling toward sustained profitability.

What could go wrong

The Vietnam competition-commission probe into fare/discount practices could result in fines or forced pricing changes in a key market, and driver protests over pay/fees signal ongoing labor friction that could raise costs. The CEO's insider selling and management's very low operating margin (2.1%) versus the seemingly stronger net margin suggest volatility in profitability that's not yet proven durable, and the $1.49B Atome deal adds integration and capital-allocation risk right when the company is trying to show consistent profits.

Fwd P/E 23.0Op margin 2.1%Rev growth 21.9%Debt/equity 28.2%Analyst upside 83.3%

How this scored 64/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 16.0%

✅ Generates cash Free cash flow $503M

✅ Not drowning in debt Debt/equity 28.2% (limit 200%)

✅ Can pay its bills Current ratio 1.5 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 8/25

Operating margin 2.1% 1/9

Net profit margin 16.0% 6/8

Return on equity 7.7% 1/8

Growth Is it getting bigger, or dying? 17/25

Revenue growth 21.9% 8/9

Earnings growth unknown 2/8

Expected profit change 24.1% 7/8

Value Is it cheap right now? 20/25

Forward P/E 23.0 5/10

PEG ratio 0.7 8/8

Analyst target upside 83.3% 7/7

Balance sheet Will it survive? 19/25

Debt / equity 28.2% 10/10

Current ratio 1.5 3/8

Free cash flow $503M 7/7

source · source · source · source · source

VCEL

🔥 HOT detected 2026-09-30 Fundamentals56/100

✓Buy: Buy — no bad news found; revenue is growing 22%, guidance was just raised, and analysts remain bullish with big upside targets.

Declined -83.9% from its all-time high of $252.80 — now $40.61

I bought this

Full analysis & scorecard›

What's going on

The stock isn't crashing on bad news — it's down modestly (8%) from a recent 30-day high after a long period of gains; in Q2 2026 Vericel actually raised full-year revenue guidance to $330-340M and announced a $200M buyback, and analysts (Leerink, Truist, TD Cowen) have reaffirmed Buy ratings with price targets around $55-58+.

The case for it

This is a profitable, fast-growing regenerative-medicine company (skin and cartilage repair products) with 22% revenue growth, a fortress balance sheet (current ratio 5x, low debt), and management just raised guidance and started buying back stock — signs of confidence, not distress. The old 2007 all-time high is irrelevant noise from a completely different company era/product mix; the real story is a business compounding revenue at 20%+ with strong cash generation ($56M FCF) that the market may be underpricing relative to analyst targets.

What could go wrong

The stock is expensive by traditional measures (84x trailing earnings, 48x forward), so any stumble in growth or margins could cause a sharp re-rating downward; operating margin is razor-thin (0.6%) meaning profits are still fragile and mostly non-operating, and insider stock sales (even if pre-planned) add some uncertainty.

Fwd P/E 48.0Op margin 0.6%Rev growth 22.5%Debt/equity 25.2%Analyst upside 49.2%

How this scored 56/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 7.9%

✅ Generates cash Free cash flow $56M

✅ Not drowning in debt Debt/equity 25.2% (limit 200%)

✅ Can pay its bills Current ratio 5.0 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 4/25

Operating margin 0.6% 0/9

Net profit margin 7.9% 3/8

Return on equity 7.2% 1/8

Growth Is it getting bigger, or dying? 19/25

Revenue growth 22.5% 8/9

Earnings growth unknown 2/8

Expected profit change 76.3% 8/8

Value Is it cheap right now? 8/25

Forward P/E 48.0 0/10

PEG ratio unknown 2/8

Analyst target upside 49.2% 6/7

Balance sheet Will it survive? 25/25

Debt / equity 25.2% 10/10

Current ratio 5.0 8/8

Free cash flow $56M 7/7

source · source · source · source

🔒

11 more picks — AI-vetted, waiting for you

The Free plan shows 3 picks. Upgrade to Pro to see every pick, the full screener, insider trades, portfolio tracking and Telegram alerts.

Unlock all picks — $29/mo